Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Cerebrolysin Dosing Protocol: 60 mg Vial — IV Infusion & Subcutaneous Guide

Cerebrolysin neurotrophic peptide mixture dosing guide — IV infusion protocol for neuroprotection, cognitive enhancement, and stroke/dementia support.

Go to peptide profileCalculate your dose

Quickstart highlights

Cerebrolysin (standardized porcine brain hydrolysate, 25% low-MW peptides) contains BDNF-, NGF-, CNTF-, and GDNF-like biological activity.

  • Concentration: 10 mg/mL if lyophilized (60 mg + 6 mL bac water); commercial liquid varies.
  • IV protocol: dilute in 100 mL saline, infuse over 60 minutes daily x 10 days under medical supervision.
  • CASTA trial: 30 mL daily IV for 10 days significantly improved NIHSS in acute ischemic stroke.
  • Ruether et al. 2001: 30 mL daily x 4 weeks improved MMSE by 3.2 points in Alzheimer's patients.
  • Subcutaneous maintenance: 60 mg weekly (6 mL) is off-label; divide across multiple injection sites.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1——IV infusion daily x 10 days10-day intensive IV infusion course: 20 mL cerebrolysin in 100 mL saline over 60 minutes daily; requires medical supervision
2-12——Subcutaneous 60 mg 1–2x weekly60 mg SC weekly (off-label maintenance) — 6 mL at 10 mg/mL; use 3 mL syringe for volume

Reconstitution steps

  1. If lyophilized: reconstitute 60 mg with 6 mL bacteriostatic water for subcutaneous use (10 mg/mL).
  2. For IV infusion: dilute in 100 mL 0.9% NaCl saline; infuse over 60 minutes only under medical supervision.
  3. Final concentration: 10 mg/mL. At 10 mg/mL: 60 mg = 6 mL — use a 10 mL syringe for IV dilution.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

10_day_iv-week plan

  • 10 vials
  • 10 syringes
  • — mL bac water
  • — alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Support neuronal survival, synaptic plasticity, and cognitive recovery through a 10-day intensive cerebrolysin IV infusion course, then maintain with weekly subcutaneous injections for neuroprotective anti-aging or post-stroke recovery.

Cycle length: 10 weeks on.

Off-cycle: 8–12 weeks off after 10-day intensive IV course.

Storage & handling

Liquid form (commercial): refrigerate at 2–8 °C; use within 30 days of opening. Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • IV infusion of cerebrolysin requires medical supervision — infuse over 60 minutes minimum to reduce risk of adverse reactions (nausea, chills).
  • Subcutaneous injection of 60 mg (6 mL) is a large volume — divide across 2–3 subcutaneous sites (2 mL per site in abdomen or thigh).
  • The 10-day IV infusion course is the most evidence-supported protocol; subcutaneous maintenance is off-label extrapolation from IV data.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Assess cognitive function using MoCA (Montreal Cognitive Assessment) at baseline and end of 10-day course.
  • Track activities of daily living (ADL) improvement for stroke or dementia patients.
  • Monitor for adverse reactions (fever, chills, rash) during and immediately after IV infusion.
Log your cycle in the calculator →

How this works & references

Cerebrolysin (standardized porcine brain hydrolysate, 25% low-MW peptides) contains BDNF-, NGF-, CNTF-, and GDNF-like biological activity. Mechanisms: (1) TrkB/TrkA receptor activation driving neuronal survival via PI3K-Akt; (2) MAPK-ERK synaptic plasticity signaling; (3) Glutamate excitotoxicity reduction (AMPA receptor modulation); (4) Amyloid precursor protein processing inhibition. In the CASTA trial (Skvortsova et al., 2006, n=208), 30 mL daily IV for 10 days significantly improved NIHSS stroke severity scores. In Alzheimer's trials, 30 mL daily x 4 weeks improved MMSE by 3.2 points versus placebo (Ruether et al., 2001).

Sources

  • Source: Ruether E et al. — Cerebrolysin in Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2001;58(12):1887-94
  • Source: Skvortsova VI et al. — Cerebrolysin in acute ischemic stroke: the CASTA trial. Stroke. 2006

Frequently asked questions

Can cerebrolysin be injected subcutaneously instead of IV?
Subcutaneous and intramuscular cerebrolysin administration is used in clinical practice in countries where it is approved (Russia, China, Austria). The bioavailability via SC/IM routes is lower than IV but still produces neurotrophic peptide exposure. The 10-day IV course remains the strongest evidence-based protocol; SC maintenance is used between IV courses.
How quickly does cerebrolysin produce cognitive effects?
In the Alzheimer's and stroke trials, meaningful cognitive improvements were measurable at 4 weeks of daily treatment. Anecdotal cognitive enhancement reports in healthy individuals suggest improved verbal fluency, memory retrieval, and processing speed within 5–10 days of IV infusion. Effects persist for 4–8 weeks post-course.
Is cerebrolysin FDA-approved?
Cerebrolysin is not FDA-approved in the US. It is approved in Austria (Ebewe Pharma), Russia, China, and many other countries for stroke, dementia, and traumatic brain injury. In the US, it is available through compounding pharmacies for research or off-label use under physician oversight.
What is the porcine prion risk with cerebrolysin?
Cerebrolysin is derived from porcine (pig) brain tissue and carries a theoretical prion risk. However: (1) manufacturing processes include heating steps that significantly reduce prion infectivity; (2) no documented cases of prion transmission from cerebrolysin have been reported; (3) pigs have no documented prion diseases analogous to bovine BSE or human CJD. The risk is considered extremely low but not zero.
Can cerebrolysin be combined with other nootropics?
Commonly combined with: (1) Semax (BDNF upregulation from different angles); (2) BPC-157 (vagal and gut-brain axis support); (3) B vitamins and acetylcholine precursors (choline, alpha-GPC) for synergistic cognitive support. No adverse interactions have been documented with these combinations.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →